Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Subjects on VYVANSE also showed greater improvement on the Clinical Global Impression-Improvement (CGI-I) rating scale compared to subjects on placebo (Study 5 in Table 6)
Still, it is a pharmacodynamically expected consequence of glucagon agonism and represents a meaningful differentiator from tirzepatide
What NJBC's Bariatric Doctor-Led Program Includes At New Jersey Bariatric Center, medical weight loss management combines access and long-term weight loss maintenance
Key Takeaways Starting dose: 2 mg once weekly for 4 weeks Titration pace: Increase every 4 weeks: 2 4 8 12 mg Maximum dose: 12 mg weekly (Phase 2/3 clinical trial protocol) Total ramp-up: ~16 weeks to reach maximum dose Mechanism: Triple agonist (GLP-1 + GIP + Glucagon), the only triple-agonist in late-stage trials Weight loss: Up to 24.2% at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3 TRIUMPH-4) GLP-3 Retatrutide Dosage Chart Free printable reference chart showing the retatrutide (GLP-3) clinical trial titration schedule from 2 mg to 12 mg weekly
